share_log

Arcutis Biotherapeutics | DEF 14A: Definitive information statements

Arcutis Biotherapeutics | DEF 14A: Definitive information statements

Arcutis Biotherapeutics | DEF 14A：股东委托书决议
美股sec公告 ·  04/27 04:39
牛牛AI助手已提取核心信息
Arcutis Biotherapeutics, Inc., a Delaware corporation, has announced its Annual Meeting of Stockholders to be held virtually on June 14, 2024. The meeting will address the election of three Class I directors, the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, the advisory approval of executive compensation, and other business as may arise. Stockholders as of April 22, 2024, are entitled to vote. The Board recommends voting for the proposed director nominees, the ratification of Ernst & Young LLP, and the approval of executive compensation. The company has also filed its definitive proxy statement with the SEC. Additionally, the company has provided a summary of the compensation of named executive officers and the opportunity for a non-binding advisory vote on executive compensation at the upcoming meeting.
Arcutis Biotherapeutics, Inc., a Delaware corporation, has announced its Annual Meeting of Stockholders to be held virtually on June 14, 2024. The meeting will address the election of three Class I directors, the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, the advisory approval of executive compensation, and other business as may arise. Stockholders as of April 22, 2024, are entitled to vote. The Board recommends voting for the proposed director nominees, the ratification of Ernst & Young LLP, and the approval of executive compensation. The company has also filed its definitive proxy statement with the SEC. Additionally, the company has provided a summary of the compensation of named executive officers and the opportunity for a non-binding advisory vote on executive compensation at the upcoming meeting.
特拉华州的一家公司Arcutis Biotherapeutics, Inc. 宣布其年度股东大会将于2024年6月14日虚拟举行。会议将讨论三名第一类董事的选举、批准安永会计师事务所为截至2024年12月31日的财政年度的独立注册会计师事务所、高管薪酬的咨询批准以及可能出现的其他事项。截至2024年4月22日，股东有权投票。董事会建议对拟议的董事候选人进行投票，批准安永会计师事务所，并批准高管薪酬。该公司还向美国证券交易委员会提交了最终委托书。此外，该公司还提供了指定执行官薪酬摘要，并提供了在即将举行的会议上就高管薪酬进行不具约束力的咨询投票的机会。
特拉华州的一家公司Arcutis Biotherapeutics, Inc. 宣布其年度股东大会将于2024年6月14日虚拟举行。会议将讨论三名第一类董事的选举、批准安永会计师事务所为截至2024年12月31日的财政年度的独立注册会计师事务所、高管薪酬的咨询批准以及可能出现的其他事项。截至2024年4月22日，股东有权投票。董事会建议对拟议的董事候选人进行投票，批准安永会计师事务所，并批准高管薪酬。该公司还向美国证券交易委员会提交了最终委托书。此外，该公司还提供了指定执行官薪酬摘要，并提供了在即将举行的会议上就高管薪酬进行不具约束力的咨询投票的机会。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

译文内容由第三方软件翻译。


牛牛AI助手部分由第三方人工智能模型基于资讯内容自动生成，只对中国内地以外的地区提供。


以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。